Literature DB >> 32649732

Characterization of post-edited cells modified in the TFAM gene by CRISPR/Cas9 technology in the bovine model.

Vanessa Cristina de Oliveira1, Clésio Gomes Mariano Junior1, José Ernesto Belizário2, José Eduardo Krieger3, Fabiana Fernandes Bressan1, Kelly Cristine Santos Roballo1,4, Paulo Fantinato-Neto1, Flávio Vieira Meirelles1, Marcos Roberto Chiaratti5, Jean-Paul Concordet6, Carlos Eduardo Ambrósio1.   

Abstract

Gene editing in large animal models for future applications in translational medicine and food production must be deeply investigated for an increase of knowledge. The mitochondrial transcription factor A (TFAM) is a member of the HMGB subfamily that binds to mtDNA promoters. This gene maintains mtDNA, and it is essential for the initiation of mtDNA transcription. Lately, we generated a new cell line through the disruption of the TFAM gene in bovine fibroblast cells by CRISPR/Cas 9 technology. We showed that the CRISPR/Cas9 design was efficient through the generation of heterozygous mutant clones. In this context, once this gene regulates the mtDNA replication specificity, the study aimed to determine if the post-edited cells are capable of in vitro maintenance and assess if they present changes in mtDNA copies and mitochondrial membrane potential after successive passages in culture. The post-edited cells were expanded in culture, and we performed a growth curve, doubling time, cell viability, mitochondrial DNA copy number, and mitochondrial membrane potential assays. The editing process did not make cell culture unfeasible, even though cell growth rate and viability were decreased compared to control since we observed the cells grow well when cultured in a medium supplemented with uridine and pyruvate. They also exhibited a classical fibroblastoid appearance. The RT-qPCR to determine the mtDNA copy number showed a decrease in the edited clones compared to the non-edited ones (control) in different cell passages. Cell staining with Mitotracker Green and red suggests a reduction in red fluorescence in the edited cells compared to the non-edited cells. Thus, through characterization, we demonstrated that the TFAM gene is critical to mitochondrial maintenance due to its interference in the stability of the mitochondrial DNA copy number in different cell passages and membrane potential confirming the decrease in mitochondrial activity in cells edited in heterozygosis.

Entities:  

Year:  2020        PMID: 32649732     DOI: 10.1371/journal.pone.0235856

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  5 in total

1.  Protocol to Study the Role of Extracellular Vesicles During Induced Stem Cell Differentiation.

Authors:  Kelly C S Roballo; Carlos E Ambrosio; Juliano C da Silveira
Journal:  Methods Mol Biol       Date:  2021

Review 2.  Mitochondrial DNA Depletion Syndrome and Its Associated Cardiac Disease.

Authors:  Haiying Wang; Yijun Han; Shenwei Li; Yunan Chen; Yafen Chen; Jing Wang; Yuqing Zhang; Yawen Zhang; Jingsuo Wang; Yong Xia; Jinxiang Yuan
Journal:  Front Cardiovasc Med       Date:  2022-02-14

3.  A Method for In Situ Reverse Genetic Analysis of Proteins Involved mtDNA Replication.

Authors:  Natalya Kozhukhar; Domenico Spadafora; Yelitza A R Rodriguez; Mikhail F Alexeyev
Journal:  Cells       Date:  2022-07-11       Impact factor: 7.666

4.  HEK293T Cells with TFAM Disruption by CRISPR-Cas9 as a Model for Mitochondrial Regulation.

Authors:  Vanessa Cristina de Oliveira; Kelly Cristine Santos Roballo; Clésio Gomes Mariano Junior; Sarah Ingrid Pinto Santos; Fabiana Fernandes Bressan; Marcos Roberto Chiaratti; Elena J Tucker; Erica E Davis; Jean-Paul Concordet; Carlos Eduardo Ambrósio
Journal:  Life (Basel)       Date:  2021-12-24

5.  TFAM-deficient mouse skin fibroblasts - an ex vivo model of mitochondrial dysfunction.

Authors:  Manuel J Del Rey; Carolina Meroño; Cristina Municio; Alicia Usategui; María Mittelbrunn; Inés García-Consuegra; Gabriel Criado; José L Pablos
Journal:  Dis Model Mech       Date:  2021-08-25       Impact factor: 5.758

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.